Eterna Therapeutics
ERNA
$1.79
Share price
3.46%
Change (1 day)
-38.49%
Change (1 year)
Categories
P/S ratio for Eterna Therapeutics (ERNA)
P/S ratio as of April 2024 (TTM): 142
According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 142.411. At the end of 2023 the company had a P/S ratio of 143.
P/S ratio history for Eterna Therapeutics from 2021 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 143 | |
| 2022 | N/A | |
| 2021 | N/A |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.44 | -98.29% | 🇫🇷 France |
 Baxter BAX | 1.37 | -99.04% | 🇺🇸 USA |
 Omeros Corporation OMER | N/A | N/A | 🇺🇸 USA |
 Geron GERN | > 1000 | 6,530.01% | 🇺🇸 USA |
 Genetic Technologies GENE | 0.5831 | -99.59% | 🇦🇺 Australia |
 Teva Pharmaceutical Industries TEVA | 0.9871 | -99.31% | 🇮🇱 Israel |
 Bio-Techne TECH | 8.80 | -93.82% | 🇺🇸 USA |